HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
HALOZYME THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$122.50+0.66 (+0.54%)
Close on Oct 19, 2026
- Market cap
- $14.85B
- P/E (TTM)
- 36.1
- Dividend yield
- –
HALOZYME THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | $307.70M | $240.68M | $257.97M | $236.04M | $205.64M | $168.19M | $170.42M | $155.06M | $124.92M | $120.59M | $122.05M | $114.43M | 64.0% | +49.6% |
| Product sales, net | $129.63M | $130.42M | $122.67M | $94.23M | $81.51M | $78.04M | $79.36M | $86.66M | $78.89M | $58.58M | $79.60M | $86.57M | 26.9% | +59.0% |
| Bulk rHuPH20 sales | $59.62M | $73.50M | – | – | $23.27M | $27.03M | – | – | – | – | – | – | 12.4% | +156.2% |
| Proprietary product sales | $55.43M | $41.87M | $59.57M | $52.24M | $46.45M | $36.34M | $47.30M | $39.93M | $44.14M | $35.25M | $39.07M | $31.51M | 11.5% | +19.3% |
| Revenues under collaborative agreements | $43.67M | $5.60M | $71.13M | $24.00M | $38.57M | $18.63M | $48.23M | $48.36M | $27.55M | $16.70M | $28.39M | $15.03M | 9.1% | +13.2% |
| Upfront license and target nomination fees | $35.50M | $0 | $18.25M | $0 | $0 | $220.00K | $0 | $27.00M | $0 | – | – | – | 7.4% | – |
| Product sales to partners | $14.58M | $15.05M | $12.86M | $9.50M | $11.79M | $14.68M | $12.37M | $15.24M | $10.11M | $12.82M | $11.29M | $18.06M | 3.0% | +23.7% |
| Event-based development and regulatory milestones and other fees | $5.71M | – | $22.50M | $0 | $24.50M | $0 | $15.00M | $18.00M | $25.50M | $14.00M | $23.00M | $13.00M | 1.2% | -76.7% |
| Device licensing and development revenue | $2.47M | $5.60M | $5.38M | $4.00M | $4.07M | $3.41M | $3.23M | $3.36M | $2.05M | $2.70M | $3.39M | $2.03M | 0.5% | -39.4% |
| Sales-based milestones | $0 | $0 | – | $20.00M | $10.00M | $15.00M | – | $0 | $0 | $0 | – | – | 0.0% | -100.0% |
| Bulk rHuPH20 sales | – | – | – | $32.49M | $23.27M | $27.03M | – | $31.49M | $24.63M | $10.51M | – | $37.00M | – | – |
| Upfront license and target nomination fees | – | – | – | – | – | $220.00K | – | $27.00M | – | $0 | $2.00M | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Halozyme Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.